Trillium reports Phase I data for TT-621 in mycosis fungoides

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported preliminary data from 10 patients with relapsed or refractory mycosis fungoides in the Phase I TTI-621-02

Read the full 224 word article

How to gain access

Continue reading with a
two-week free trial.